Abstract
BackgroundDenosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by inhibiting RANKL, a key mediator of osteoclast formation, function, and survival.ObjectivesTo evaluate the effect of denosumab...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have